IL-23/Th17 targeted therapies in SAPHO syndrome. A case series

We report the results of six courses of IL-23 and IL-17 targeted therapies (3 ustekinumab and 3 secukinumab) in patients with SAPHO syndrome unresponsive to previous treatments (csDMARDs and bDMARDs). With a mean treatment duration of 5.5 months, improvement of skin symptoms was noticed in three cases, one improvement with secukinumab, and two remissions (one with secukinumab, one with ustekinumab). Regarding the rheumatic symptoms, no major improvement was obvious under any of the six treatment courses. No particular safety concerns were reported, except cases of paradoxical psoriasis flare in one under ustekinumab, and the other case under secukinumab.
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research

Related Links:

Authors: Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, Downs A, Landeira M, Bewley A Abstract Psoriasis can adversely affect quality of life (QoL) and emotional well-being. In this UK prospective observational study we evaluated the 'real-world' impact of adalimumab on QoL and the physical/psychological effects of moderate-to-severe psoriasis. 143 biologic-naïve patients with moderate-to-severe psoriasis, receiving adalimumab in clinical practice, were included. Patients completed a series of questionnaires at baseline (adalimumab initiation), 4 and 16-weeks and 6-months post-adalimumab initiation...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
CONCLUSION: Beliefs, previous experience of using CHM, desire to prevent relapse, and safety are important motivators for choosing CHM in people with psoriasis vulgaris and chronic urticaria. Further clinical evidence is required to enable patients to make informed clinical decision. Patient preferences should be considered in the context of available evidence when prescribing CHM. PMID: 30897010 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
EXCLUSIVE: Jude Osborne, 45, Lucy Jones, 40, and Dave Brooks, 54, from the UK, saw 95 per cent of their flaky, dry skin calmed by Soratinex products.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Condition:   Generalized Pustular Psoriasis Intervention:   Drug: BI 655130 Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: May 2019Source: Molecular Immunology, Volume 109Author(s): Hongxing Shen, Lewis Zhichang ShiAbstractIL-17-producing TH17 cells have been associated with autoimmune diseases such as multiple sclerosis (MS), psoriasis, Crohn’s disease, and ulcerative colitis (Han et al., 2015), many of which lack effective therapies. Identifying effective approaches to selectively suppress TH17 cell development and function represents a legitimate strategy to cure these autoimmune disorders. TH17 cell differentiation requires rewiring of their metabolic program, transition from the oxidative phosphorylation-dominant c...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Authors: Wang Q, McCormick TS, Ward NL, Cooper KD, Conic R, Xu R Abstract Psoriasis is a chronic, debilitating skin condition that affects approximately 125 million individuals worldwide. The cause of psoriasis appears multifactorial, and no unified mitigating signal or single antigenic target has been identified to date. Metabolomic studies hold great potential for explaining disease mechanism, facilitating early diagnosis, and identifying potential therapeutic areas. Here, we present an integrated disease metabolomic biomarker discovery strategy that combines mechanism-based biomarker discovery with clinical samp...
Source: AMIA Annual Symposium Proceedings - Category: Bioinformatics Tags: AMIA Annu Symp Proc Source Type: research
Kim Kardashian drinks celery juice to help her psoriasis. But Emma Wedgeworth, a dermatologist from London, said it increases the skin's sensitivity to UVA in sunlight.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conditions:   Psoriasis Vulgaris;   Psoriasis Arthropathica;   Pustular Psoriasis;   Erythrodermic Psoriasis Intervention:   Drug: Infliximab [infliximab biosimilar 3] Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Ling YL, Huang X, Mitri G, Lovelace B, Pham, Knobler R, Li X, Gao X Abstract INTRODUCTION: The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). OBJECTIVE: To investigate real-world use of ECP in CTCL patients in the US. METHODS: Data from the Truven MarketScan® database (2010-2015) were used to create a cohort of CTCL patients receiving systemic treatment. Multivariable regressions were performed to compare health care resource utilizatio...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
CONCLUSION: Biologics have a superior drug survival rate than conventional therapies. Ustekinumab is the biologic with the longest drug survival, only affected by the gradual loss of efficacy assumed for biological therapies. PMID: 30888880 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Men | Orthopaedics | Psoriasis | Rheumatology | Skin | Stelara